Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post‐transplantation. Issue 6 (16th January 2015)

• Record Type: Journal Article
• Authors: Koh, Kyung‐Nam; Im, Ho Joon; Suh, Jin Kyung; Lee, Seong Wook; Choi, Eun Seok; Seo, Jong Jin
• Is Part Of: Pediatric blood & cancer. Volume 62:Issue 6(2015:Jun.)
• Page Start: 1063
• Page End: 1065
• Publication Date: 2015-01-16
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25351
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25351-sec-0001" sec-type="section"> <p>Brentuximab vedotin (BV) is a monoclonal antibody‐drug conjugate that targets CD30, and has been reported to be effective for relapsed/refractory anaplastic large cell lymphoma. We here report a patient who experienced multiple relapses after conventional chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). He achieved a complete metabolic response with BV and proceeded to undergo haploidentical HSCT. After HSCT, he received three doses of BV to prevent an early relapse, and remains in remission 16 months post‐transplantation. Our case suggests the potential use of BV both as a bridging therapy to allogeneic HSCT and as a maintenance therapy post‐transplantation. Pediatr Blood Cancer 2015;62:1063–1065. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>